NCT05001061

Brief Summary

Efficacy of sublingual versus vaginal misoprostol in termination of first trimester missed abortion

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
288

participants targeted

Target at P75+ for early_phase_1

Timeline
Completed

Started Aug 2021

Shorter than P25 for early_phase_1

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 2, 2021

Completed
1 day until next milestone

Study Start

First participant enrolled

August 3, 2021

Completed
8 days until next milestone

First Posted

Study publicly available on registry

August 11, 2021

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 15, 2021

Completed
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 16, 2021

Completed
Last Updated

August 11, 2021

Status Verified

August 1, 2021

Enrollment Period

2 months

First QC Date

August 2, 2021

Last Update Submit

August 6, 2021

Conditions

Outcome Measures

Primary Outcomes (2)

  • The occurance of complete abortion within 24 hours with Misoprostol drug

    Efficacy of sublingual and vaginal Misoprostol in complete termination of first trimester missed abortion

    Within 24 hours

  • Which route is the best and less side effects in complete termination of first trimester missed abortion by Misoprostol drug

    Vaginal versus sublingual route of administration of Misoprostol for complete termination of first trimester missed abortion

    within 24 hours

Study Arms (2)

Sublingual Misoprostol for termination of first trimester missed abortion

ACTIVE COMPARATOR

Patients diagnosed as first trimester missed abortion will receive sublingual Misoprostol 800 micrograms every 4 hours up to five doses

Drug: Misoprostol Pill

Vaginal Misoprostol for termination of first trimester missed abortion

ACTIVE COMPARATOR

Patients diagnosed as first trimester missed abortion will receive vaginal Misoprostol 800 micrograms every 4 hours up to five doses

Drug: Misoprostol Pill

Interventions

sublingual versus vaginal Misoprostol in termination of first trimester missed abortion

Sublingual Misoprostol for termination of first trimester missed abortionVaginal Misoprostol for termination of first trimester missed abortion

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Women with an ultrasound diagnosis of missed abortion \< 13 weeks gestation without any clinical criteria of Inevitable abortion.

You may not qualify if:

  • Patients refused the medical treatment.
  • Patients have contraindications of the drug (Misoprostol).
  • Missed abortion associated with any signs of sepsis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (2)

  • Allameh Z, Goharian M, Eslamian M. Effect of misoprostol with and without letrozole on the induction of abortion for women with first-trimester missed abortion. Int J Gynaecol Obstet. 2020 Nov;151(2):214-218. doi: 10.1002/ijgo.13326. Epub 2020 Sep 1.

    PMID: 32700359BACKGROUND
  • Tang OS, Gemzell-Danielsson K, Ho PC. Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. Int J Gynaecol Obstet. 2007 Dec;99 Suppl 2:S160-7. doi: 10.1016/j.ijgo.2007.09.004. Epub 2007 Oct 26.

    PMID: 17963768BACKGROUND

MeSH Terms

Conditions

Abortion, Missed

Interventions

Misoprostol

Condition Hierarchy (Ancestors)

Abortion, SpontaneousPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital Diseases

Intervention Hierarchy (Ancestors)

Prostaglandins E, SyntheticProstaglandins, SyntheticProstaglandinsEicosanoidsFatty Acids, UnsaturatedFatty AcidsLipidsAutacoidsInflammation MediatorsBiological Factors

Central Study Contacts

Study Design

Study Type
interventional
Phase
early phase 1
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Resident in obstetrics and gynecology

Study Record Dates

First Submitted

August 2, 2021

First Posted

August 11, 2021

Study Start

August 3, 2021

Primary Completion

October 15, 2021

Study Completion

October 16, 2021

Last Updated

August 11, 2021

Record last verified: 2021-08